Zealand Pharma Revenue vs. Earnings Per Share

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZP</div>
ZEAL -- Denmark Stock  

DKK 247.60  18.80  7.06%

The Drivers Module shows relationships between Zealand Pharma's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of Zealand Pharma AS over time as well as its relative position and ranking within its peers. Check out Your Current Watchlist

Search Current Fundamental Trends

 
Refresh
Sales per Share is projected to rize to 1.46 this yearZealand Pharma Operating Income is quite stable at the moment as compared to the last year. The company current value of Operating Income is estimated at about 633.51 Million. Net Income Per Employee is projected to rize to about 3.8 M this year, although the value of Net Income will most likely fall to (508.2 M).

Zealand Pharma AS Earnings Per Share vs. Revenue Fundamental Analysis

Zealand Pharma AS is rated second in revenue category among related companies. It is rated second in earnings per share category among related companies . . Zealand Pharma Revenues is quite stable at the moment as compared to the last year. The company current value of Revenues is estimated at about 42.96 Million
Zealand Pharma AS is rated second in revenue category among related companies. Market size based on revenue of Biotechnology industry is at this time estimated at about 85.92 Million. Zealand Pharma totals roughly 42.96 Million in revenue claiming about 50% of stocks in Biotechnology industry.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and is an essential item when evaluating financial statements of a company. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Zealand Pharma 
Revenue 
 = 
Money Received 
Discounts and Returns 
=
42.96 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Zealand Pharma 
Earnings per Share 
 = 
Earnings 
Average Shares 
=
(15.71) 
Earnings per Share is one of the most critical measures of the current share price of a firm, and is used by investors to determine the overall company profitability; especially when it is compared to the EPS of similar companies.

Zealand Earnings Per Share Comparison

Zealand Fundamental Comparison

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page